Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ABBV NASDAQ:ALEC NASDAQ:AMLX NASDAQ:ATHA NASDAQ:COYA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$217.92-0.2%$200.86$163.81▼$221.76$385.71B0.534.35 million shs5.16 million shsALECAlector$2.96+7.6%$2.08$0.87▼$6.37$278.33M0.991.24 million shs919,745 shsAMLXAmylyx Pharmaceuticals$11.85+1.7%$8.74$2.59▼$12.25$1.04B-0.451.83 million shs1.93 million shsATHAAthira Pharma$0.38+6.7%$0.40$0.22▼$0.83$14.20M3.01155,634 shs284,154 shsCOYACoya Therapeutics$5.68-6.1%$6.24$4.65▼$10.24$101.19M0.26102,888 shs131,304 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie-0.22%+3.79%+5.45%+17.53%+12.21%ALECAlector+7.64%+7.25%+31.56%+94.74%-50.91%AMLXAmylyx Pharmaceuticals+1.72%+13.51%+48.13%+122.33%+352.29%ATHAAthira Pharma+6.69%-0.23%-4.14%+19.32%-27.27%COYACoya Therapeutics-6.12%-10.83%-7.64%+6.77%-11.25%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$217.92-0.2%$200.86$163.81▼$221.76$385.71B0.534.35 million shs5.16 million shsALECAlector$2.96+7.6%$2.08$0.87▼$6.37$278.33M0.991.24 million shs919,745 shsAMLXAmylyx Pharmaceuticals$11.85+1.7%$8.74$2.59▼$12.25$1.04B-0.451.83 million shs1.93 million shsATHAAthira Pharma$0.38+6.7%$0.40$0.22▼$0.83$14.20M3.01155,634 shs284,154 shsCOYACoya Therapeutics$5.68-6.1%$6.24$4.65▼$10.24$101.19M0.26102,888 shs131,304 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie-0.22%+3.79%+5.45%+17.53%+12.21%ALECAlector+7.64%+7.25%+31.56%+94.74%-50.91%AMLXAmylyx Pharmaceuticals+1.72%+13.51%+48.13%+122.33%+352.29%ATHAAthira Pharma+6.69%-0.23%-4.14%+19.32%-27.27%COYACoya Therapeutics-6.12%-10.83%-7.64%+6.77%-11.25%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABBVAbbVie 2.92Moderate Buy$220.431.15% UpsideALECAlector 2.29Hold$4.1740.77% UpsideAMLXAmylyx Pharmaceuticals 3.00Buy$13.2511.81% UpsideATHAAthira Pharma 2.00Hold$0.5030.17% UpsideCOYACoya Therapeutics 3.00Buy$16.50190.49% UpsideCurrent Analyst Ratings BreakdownLatest AMLX, ALEC, ABBV, ATHA, and COYA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/16/2025ABBVAbbVieJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$200.00 ➝ $235.009/15/2025ABBVAbbVieCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$215.00 ➝ $245.009/15/2025AMLXAmylyx PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$17.00 ➝ $25.009/12/2025ABBVAbbVieWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$240.00 ➝ $260.009/12/2025ABBVAbbVieBMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$215.00 ➝ $240.009/4/2025COYACoya TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.008/28/2025AMLXAmylyx PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00 ➝ $14.008/25/2025ABBVAbbVieRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform8/25/2025COYACoya TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.008/25/2025COYACoya TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.008/13/2025COYACoya TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABBVAbbVie$56.33B6.83$14.91 per share14.62$1.90 per share114.69ALECAlector$81.13M3.69N/AN/A$1.29 per share2.29AMLXAmylyx Pharmaceuticals$87.37M12.09N/AN/A$2.40 per share4.94ATHAAthira PharmaN/AN/AN/AN/A$1.16 per shareN/ACOYACoya Therapeutics$3.55M26.77N/AN/A$2.37 per share2.40Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABBVAbbVie$4.28B$2.10103.7715.591.406.45%699.66%13.64%10/29/2025 (Estimated)ALECAlector-$119.05M-$1.16N/AN/AN/A-142.10%-112.06%-26.37%11/5/2025 (Estimated)AMLXAmylyx Pharmaceuticals-$301.74M-$2.50N/AN/AN/AN/A-82.48%-70.15%11/6/2025 (Estimated)ATHAAthira Pharma-$96.94M-$1.55N/AN/AN/AN/A-139.40%-106.84%11/6/2025 (Estimated)COYACoya Therapeutics-$14.88M-$1.24N/AN/AN/AN/A-61.05%-53.61%11/5/2025 (Estimated)Latest AMLX, ALEC, ABBV, ATHA, and COYA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025COYACoya Therapeutics-$0.22-$0.36-$0.14-$0.36$0.78 million$0.16 million8/7/2025Q2 2025ALECAlector-$0.45-$0.30+$0.15-$0.30$2.76 million$7.87 million8/7/2025Q2 2025AMLXAmylyx Pharmaceuticals-$0.44-$0.46-$0.02-$0.46N/AN/A8/7/2025Q2 2025ATHAAthira Pharma-$0.18-$0.18N/A-$0.18N/AN/A7/31/2025Q2 2025ABBVAbbVie$3.24$2.97-$0.27$0.52$14.93 billion$15.42 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABBVAbbVie$6.563.01%N/A312.38%53 YearsALECAlectorN/AN/AN/AN/AN/AAMLXAmylyx PharmaceuticalsN/AN/AN/AN/AN/AATHAAthira PharmaN/AN/AN/AN/AN/ACOYACoya TherapeuticsN/AN/AN/AN/AN/ALatest AMLX, ALEC, ABBV, ATHA, and COYA DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date9/5/2025ABBVAbbViequarterly$1.643.08%10/15/202510/15/202511/14/20256/20/2025ABBVAbbViequarterly$1.643.54%7/15/20257/15/20258/15/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABBVAbbVie44.140.740.61ALECAlector0.133.783.78AMLXAmylyx PharmaceuticalsN/A8.728.72ATHAAthira PharmaN/A10.8110.81COYACoya TherapeuticsN/A7.437.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABBVAbbVie70.23%ALECAlector85.83%AMLXAmylyx Pharmaceuticals95.84%ATHAAthira Pharma57.12%COYACoya Therapeutics39.75%Insider OwnershipCompanyInsider OwnershipABBVAbbVie0.08%ALECAlector9.70%AMLXAmylyx Pharmaceuticals12.30%ATHAAthira Pharma19.80%COYACoya Therapeutics12.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABBVAbbVie55,0001.77 billion1.77 billionOptionableALECAlector270101.21 million91.39 millionOptionableAMLXAmylyx Pharmaceuticals20089.17 million78.20 millionOptionableATHAAthira Pharma4039.44 million31.63 millionOptionableCOYACoya Therapeutics616.73 million14.72 millionNot OptionableAMLX, ALEC, ABBV, ATHA, and COYA HeadlinesRecent News About These CompaniesCoya Therapeutics' COYA 303 Shows Promising Central Nervous System (CNS) Anti-inflammatory Effects and Systemic Regulatory T Cell (Treg) Enhancing Effects in a Preclinical Animal Inflammation Model1 hour ago | prnewswire.comD. Boral Capital Reiterates Buy Rating for Coya Therapeutics (NASDAQ:COYA)September 6, 2025 | marketbeat.comCoya Therapeutics' (COYA) Buy Rating Reiterated at D. Boral CapitalSeptember 6, 2025 | americanbankingnews.comCoya Therapeutics' COYA 302 ALS Trial Accepted by NEALS as a NEALS-Affiliated TrialSeptember 4, 2025 | prnewswire.comPRISM MarketView Features Exclusive Q&A with Coya Therapeutics CEO Arun Swaminathan on Targeting Neurodegenerative Diseases Through Treg TherapiesSeptember 3, 2025 | globenewswire.comCoya Therapeutics to Participate at Upcoming September Investor ConferencesSeptember 3, 2025 | prnewswire.comHC Wainwright Issues Optimistic Forecast for COYA EarningsAugust 29, 2025 | marketbeat.comCoya Therapeutics to progress trial of ALS treatment upon FDA approvalAugust 28, 2025 | pharmatimes.comPCoya Therapeutics, Inc. (COYA) Now Trades Above Golden Cross: Time to Buy?August 27, 2025 | zacks.comCoya Therapeutics (NASDAQ:COYA) Receives "Buy" Rating from D. Boral CapitalAugust 27, 2025 | marketbeat.comCoya Therapeutics (NASDAQ:COYA) Receives Buy Rating from HC WainwrightAugust 27, 2025 | marketbeat.comCoya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)August 27, 2025 | finance.yahoo.comFDA approves Coya Therapeutics’ trial of COYA 302 for ALSAugust 26, 2025 | msn.comAfter month-long delay, Coya Therapeutics receives FDA go-ahead for ph. 2 ALS trialAugust 25, 2025 | fiercebiotech.comFCoya Therapeutics stock soars after FDA accepts IND for ALS treatmentAugust 25, 2025 | za.investing.comLack of resources at FDA extends clinical hold on ALS drug NUZ-001August 21, 2025 | alsnewstoday.comANeurizon becomes second biotech hit with FDA delay for ALS candidateAugust 19, 2025 | fiercebiotech.comFFDA review timeline extended for NUZ-001 IND clinical holdAugust 19, 2025 | thepharmaletter.comTChardan Capital Has Bullish Outlook for COYA FY2025 EarningsAugust 19, 2025 | marketbeat.comCoya Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues LagAugust 14, 2025 | finance.yahoo.comCoya Therapeutics Reports Increased Losses Amid Development FocusAugust 12, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025Renaissance Hedge Fund Adds NVIDIA, Follows Buffett Into UNHBy Leo Miller | August 20, 2025With Rate Cuts Ahead, Buffett-Backed Builders Look Like a BuyBy Jordan Chussler | September 4, 2025Constellation Lowers Outlook: Time to Panic on Buffett's Big Bet?By Leo Miller | September 12, 2025AMLX, ALEC, ABBV, ATHA, and COYA Company DescriptionsAbbVie NYSE:ABBV$217.92 -0.42 (-0.19%) Closing price 09/15/2025 03:59 PM EasternExtended Trading$216.83 -1.09 (-0.50%) As of 08:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.Alector NASDAQ:ALEC$2.96 +0.21 (+7.64%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$2.94 -0.02 (-0.81%) As of 08:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.Amylyx Pharmaceuticals NASDAQ:AMLX$11.85 +0.20 (+1.72%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$11.80 -0.04 (-0.38%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Athira Pharma NASDAQ:ATHA$0.38 +0.02 (+6.69%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$0.38 -0.01 (-2.11%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.Coya Therapeutics NASDAQ:COYA$5.68 -0.37 (-6.12%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$5.75 +0.07 (+1.23%) As of 08:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
